Advertisement
ALMS vs MRNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALMS is a Hold and MRNA is a Hold.
ALMS in -14.16% downward trend, sliding for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALMS declined for three days, in 131 of 147 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALMS as a result. In 34 of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ALMS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for ALMS just turned positive on September 22, 2026. Looking at past instances where ALMS's MACD turned positive, the stock continued to rise in 16 of 18 cases over the following month. The odds of a continued upward trend are 89%.
Following a +5.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMS advanced for three days, in 100 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
ALMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.752) is normal, around the industry mean (26.823). P/E Ratio (-1.489) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (123.457) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. ALMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MRNA's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for MRNA moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 25 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on MRNA as a result. In 71 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on October 12, 2026. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Following a +9.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 212 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 99 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 1 (best 1 - 100 worst), indicating outstanding price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.873) is normal, around the industry mean (26.823). P/E Ratio (-27.320) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MRNA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 1 | |
P/E GROWTH RATING 1..100 | 3 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ALMS | MRNA | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 76% | 3 days ago 78% |
| Momentum ODDS (%) | 3 days ago 87% | 3 days ago 82% |
| MACD ODDS (%) | 3 days ago 89% | 3 days ago 88% |
| TrendWeek ODDS (%) | 3 days ago 89% | 3 days ago 85% |
| TrendMonth ODDS (%) | 3 days ago 88% | 3 days ago 80% |
| Advances ODDS (%) | 10 days ago 77% | 4 days ago 78% |
| Declines ODDS (%) | 5 days ago 89% | 18 days ago 87% |
| BollingerBands ODDS (%) | 3 days ago 76% | 3 days ago 79% |
| Aroon ODDS (%) | 3 days ago 81% | 3 days ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALMS’s FA Score shows that 1 FA rating(s) are green while MRNA’s FA Score has 2 green FA rating(s).
- ALMS’s FA Score: 1 green, 4 red.
- MRNA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALMS’s TA Score shows that 4 TA indicator(s) are bullish while MRNA’s TA Score has 4 bullish TA indicator(s).
- ALMS’s TA Score: 4 bullish, 3 bearish.
- MRNA’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALMS (@Biotechnology) experienced а -14.53% price change this week, while MRNA (@Biotechnology) price change was -3.11% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.
Reported Earning Dates
ALMS is expected to report earnings on Nov 12, 2026.
MRNA is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (-10.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALMS and
Correlation & Price change
A.I.dvisor tells us that ALMS and DRUG have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALMS and DRUG's prices will move in lockstep.
| Ticker / NAME | Correlation To ALMS | 1D Price Change % | ||
|---|---|---|---|---|
| ALMS | 100% | -3.01% | ||
| DRUG - ALMS | 31% Poorly correlated | -5.37% | ||
| MRNA - ALMS | 30% Poorly correlated | -7.82% | ||
| ZNTL - ALMS | 28% Poorly correlated | -4.91% | ||
| ARVN - ALMS | 28% Poorly correlated | -2.65% | ||
| VKTX - ALMS | 27% Poorly correlated | -8.04% | ||
More | ||||